stage 3 Multiple Myeloma (MM) (DBCOND0154151)

Identifiers

Synonyms
Multiple Myeloma Stage III / Stage III Multiple Myeloma

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03428373
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myelomatreatment2 / 3active_not_recruiting
NCT06485076
Early Palliative Care for Patients With Multiple Myeloma and Aggressive LymphomaNo drug interventionssupportive_careNot Availablerecruiting
NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancersupportive_care2completed
NCT00047203
Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myelomatreatment2completed
NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancersupportive_careNot Availablecompleted
NCT00028821
2-Methoxyestradiol in Treating Patients With Advanced Solid Tumorstreatment1completed
NCT00619684
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplanttreatment2completed
NCT01534143
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplanttreatment2terminated
NCT00002787
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantationtreatment1completed
NCT00693433
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myelomatreatment1completed
NCT00006251
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancertreatment1 / 2completed
NCT00085345
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myelomatreatment2withdrawn
NCT00410605
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myelomatreatment2completed
NCT02082405
Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myelomatreatment2withdrawn
NCT00019097
Vaccine Therapy in Treating Patients With Multiple Myelomatreatment2completed
NCT00303797
Sorafenib and Bortezomib in Treating Patients With Advanced Cancertreatment1completed
NCT00054483
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunctionbasic_science1completed
NCT01849783
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myelomatreatment2completed
NCT01676961
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapysupportive_care2terminated
NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphomatreatment1completed
NCT00079456
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myelomatreatment2completed
NCT00002556
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myelomatreatment3completed
NCT00398515
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myelomatreatment1completed
NCT00514137
Sunitinib in Treating Patients With Relapsed Multiple Myelomatreatment2completed
NCT00998049
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplanttreatment2completed
NCT00437034
Aflibercept for Relapsed Multiple Myelomatreatment2terminated
NCT00310024
Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myelomatreatment1completed
NCT00014235
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciestreatmentNot Availablecompleted
NCT00243035
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myelomatreatment1 / 2terminated
NCT00003166
Bryostatin and Vincristine in B-Cell Malignanciestreatment1completed
NCT01074060
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myelomatreatment1completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00522392
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasonetreatment3terminated
NCT01159067
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overloadsupportive_care2terminated
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00060372
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancertreatment1completed
NCT00075881
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myelomatreatment2completed
NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplantsupportive_careNot Availablecompleted
NCT01954784
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myelomatreatment1terminated
NCT00112879
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myelomatreatment2withdrawn
NCT00003954
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myelomatreatment1 / 2completed
NCT00849251
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myelomatreatment1 / 2terminated
NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsNo drug interventionssupportive_care3completed
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT01816971
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myelomatreatment2active_not_recruiting
NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomatreatmentNot Availablecompleted
NCT01588015
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_care1completed
NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciestreatmentNot Availableterminated
NCT00118170
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Functiontreatment1completed
NCT01653106
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma PatientsNo drug interventionstreatmentNot Availablecompleted
NCT00003196
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomatreatmentNot Availablecompleted
NCT00182663
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplanttreatment2completed
NCT01057225
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myelomatreatment1 / 2completed
NCT01706666
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplanttreatment2completed
NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignanciessupportive_care2completed
NCT01518465
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myelomatreatment2terminated
NCT01812720
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplanttreatment2withdrawn
NCT00112827
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myelomatreatment1 / 2completed
NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerNo drug interventionssupportive_careNot Availablecompleted
NCT02224729
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myelomatreatment2completed
NCT00006244
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myelomatreatment2completed
NCT00719901
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myelomatreatment1 / 2terminated
NCT00795769
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplantsupportive_care2completed
NCT01427881
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignanciestreatment2completed
NCT00112723
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myelomatreatment1 / 2terminated
NCT00217438
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myelomatreatment3completed